RhondaH
06-09-2006, 04:53 PM
Have any others seen this? Michele, is this the trial you participated in? Any info on?
Rhonda
Grant Update!
Encouraging News for Breast/Ovarian Cancer Patients
CTRF recently talked with Dr. Nora Disis from the University
of Washington about the outcome of her study entitled
“Combination Immunotherapy for the Generation of HER-
2/neu [HER2] Specific Cytoxic T-Cells [CTL] in Vivo.”
“Funding from CTRF has allowed us to develop two new
types of cancer treatment. First are vaccines for the prevention
of cancer relapse. We have been able to demonstrate
that HER2 is an immunogenic protein and that breast and ovarian cancer
patients can be immunized against HER2. In Phase I studies we have shown
that immunity can persist as long as 7 years at the end of immunization.
Phase II studies evaluating prevention of relapse are underway. Secondly,
we showed that after vaccination you can prime T-Cells very readily to grow in
vitro. This has allowed us to expand tumor specific T-Cells outside the body
and infuse them into breast and ovarian cancer patients literally supplying
them with an immune system that can recognize their tumor. Our initial Phase
I studies have been promising in that even advanced stage heavily treated
cancer patients have demonstrated clinical responses.”
Further research will be done with the National Institute of
Health/Department of Defense as a follow-up to CTRF funding.
For a more in-depth look at Dr. Disis’s study, see the Journal of Clinical Oncology May 15, 2004 issue.
Rhonda
Grant Update!
Encouraging News for Breast/Ovarian Cancer Patients
CTRF recently talked with Dr. Nora Disis from the University
of Washington about the outcome of her study entitled
“Combination Immunotherapy for the Generation of HER-
2/neu [HER2] Specific Cytoxic T-Cells [CTL] in Vivo.”
“Funding from CTRF has allowed us to develop two new
types of cancer treatment. First are vaccines for the prevention
of cancer relapse. We have been able to demonstrate
that HER2 is an immunogenic protein and that breast and ovarian cancer
patients can be immunized against HER2. In Phase I studies we have shown
that immunity can persist as long as 7 years at the end of immunization.
Phase II studies evaluating prevention of relapse are underway. Secondly,
we showed that after vaccination you can prime T-Cells very readily to grow in
vitro. This has allowed us to expand tumor specific T-Cells outside the body
and infuse them into breast and ovarian cancer patients literally supplying
them with an immune system that can recognize their tumor. Our initial Phase
I studies have been promising in that even advanced stage heavily treated
cancer patients have demonstrated clinical responses.”
Further research will be done with the National Institute of
Health/Department of Defense as a follow-up to CTRF funding.
For a more in-depth look at Dr. Disis’s study, see the Journal of Clinical Oncology May 15, 2004 issue.